“Ozempic Butt”: The Shape Change Nobody Mentions

The formula worked again

"Ozempic face" was a good enough coinage that the culture immediately looked for somewhere else to put it. Ozempic teeth. Ozempic feet. And, far bigger than any of them, Ozempic butt — a phrase now typed into a search bar roughly twenty-three thousand times a month in the United States, on our analysis of third-party keyword data, which makes it one of the most-searched side effects of a drug class whose labels do not mention it.

The formula is always the same, and it is always half-true. A real thing happens to a body during fast, substantial weight loss. A brand name gets stapled to the front of it. And the staple does the work of an argument: it implies the medication did something particular to your backside, when what the medication did was help you lose thirty or fifty pounds, which is a thing that has always changed a backside.

That does not make the change imaginary, and this piece is not going to tell you it is in your head. It is going to tell you what is actually leaving, why the seat and hips read the change more loudly than most places, and which of the available responses are worth your time.

Three different things wearing one name

When women describe "Ozempic butt" they are usually describing one of three changes, and they respond to completely different interventions.

• Volume. The fat that gave the area its shape is gone, so the silhouette flattens.
• Muscle. The glutes underneath have lost mass, which changes projection and the way clothes sit.
• Skin. The envelope has not caught up, so the surface reads crepey or loose.

Most women get some of all three. The proportions are what decide what helps.

The muscle part is the one with the hardest numbers behind it, and it is the one nobody mentions in the marketing. A network meta-analysis of twenty-two randomised trials and 2,258 participants found that GLP-1 receptor agonists reduced total body weight by an average of 3.55 kg, fat mass by 2.95 kg — and lean mass by 0.86 kg, which works out at roughly a quarter of everything lost¹. Semaglutide 2.4 mg and tirzepatide 15 mg came out as the most effective for weight and fat, and among the least effective at holding onto lean tissue. A narrative review in Diabetes Care puts the same finding in blunter terms: incretin therapy causes a loss of lean mass in the region of 10%, or about 6 kg, which the authors compare to a decade or more of ageing².

Six kilograms of lean tissue does not come off your forearms. Some of it comes off the largest muscle group you own.

Why the seat reads it loudest

There is a second reason this lands harder on a woman's lower half than on a man's, and it is not vanity.

Female fat distribution is weighted toward the hips, buttocks and thighs — the gluteofemoral depot — and that tissue behaves differently from the fat around the middle. It turns over more slowly, and a substantial body of metabolic research treats a larger gluteofemoral depot as protective rather than incidental³. It is also, in practice, a great deal of what gives a woman her outline. So when a body composed on that plan loses a fifth of its weight, the change does not distribute politely. It shows up where the fat was.

Fat does not leave a body evenly, and it never has. The medication did not choose your hips. Your body stored them there in the first place.

The skin, which is the slow half

The other half of the complaint is the envelope, and it is the part the plastic surgeons get asked about. Dermatologists interviewed by TODAY were consistent, and notably unhysterical, about it. "Because the weight loss can be so rapid" on these drugs, users may see sagging skin, said F. Clarissa Yang, dermatologist-in-chief at Tufts Medical Center — "however, you can see this with any rapid weight loss." Samuel Lin, a Boston plastic surgeon and associate professor of surgery at Harvard Medical School, offered the image everyone reaches for: "Think of a balloon that's losing air. As the balloon deflates, you notice wrinkles and extra material where the air once filled."⁴

Age is the variable nobody can negotiate. Collagen and elastin thin over a life, so the same weight loss at forty-four produces more slack than it would have at twenty-four. And the two problems compound each other — Boise dermatologist Dustin Portela told the same report that if you lose a significant amount of both muscle and fat from the buttocks, the sagging skin can appear even more pronounced⁴. Deflate the volume and the envelope has further to fall.

If loose skin rather than shape is your actual complaint, the longer version of that story — including what body-contouring surgery does and does not fix — is in our loose-skin piece.

What actually protects it

Here is the useful part, and it is unglamorous enough that almost nobody builds a business on it.

Resistance training is the only intervention with real leverage. The same Diabetes Care review that quantified the lean-mass problem also quantified the answer: supervised resistance training lasting more than ten weeks produces large gains in lean mass, around 3 kg, and about 25% in strength, in both men and women². That is the single thing on this page that changes the outcome rather than describing it. Glutes respond to load. They do not respond to being worried about.

Eat enough protein while you are losing. Appetite suppression that works is appetite suppression that makes it easy to under-eat protein, which is precisely the wrong thing to do while the scale is moving.

Give it time before you decide. The most encouraging real-world data on this comes from the SEMALEAN study, which followed 106 adults with obesity on semaglutide 2.4 mg with DXA scans and grip-strength testing. Lean mass fell about 3 kg by month seven and then stabilised; handgrip strength improved by 4.5 kg at twelve months, and the prevalence of sarcopenic obesity in the group fell from 49% at baseline to 33%⁵. That is not a promise, and the group was not randomised. But it is a real cohort in which function got better while the number on the DXA scan got worse, which is a useful corrective to a scan read in isolation.

What the manufacturer says, which is almost nothing

The last thing worth knowing is how thin the evidence under this phrase actually is.

Asked about reports of Ozempic butt, a Novo Nordisk spokesperson told TODAY plainly: "We do not have clinical data evaluating the effect of Wegovy or Ozempic on sagging skin on the buttocks."⁴ No trial has photographed a backside, measured gluteal volume, or scored the skin over it. What exists is body-composition data that tells you tissue is leaving, and a very large amount of public anxiety about where.

That anxiety is itself measurable, and it moves money. The systematic review of "Ozempic face" in the plastic-surgery literature tracked what people did with the phrase and found searches for it running alongside rising searches for facial filler and for plastic surgeons⁶. The same pipeline is now open one storey down, and it is worth walking into it knowing that the panic arrived before the evidence did.

None of which means the change is trivial. In a survey of 1,659 people using these medications, more than half had been trying to lose weight for over a decade before they started. Participants reported that the drug quietened food-related thoughts and improved satiety — and named body satisfaction, not a lab value, as a core motivator for being on it at all⁷. Women who came to this for how they wanted to look are entitled to have an opinion about how they now look, without being told they are being shallow about a drug that was sold to them on exactly that basis.

Lift heavy things. Eat the protein. Wait longer than four months before you conclude anything. And take the shape question to the clinician who prescribed the dose, because a slower titration is a real option and nobody will offer it to you unprompted.